Document Detail


Cytogenetic and molecular genetic evolution of chronic myeloid leukemia.
MedLine Citation:
PMID:  11919388     Owner:  NLM     Status:  MEDLINE    
Abstract/OtherAbstract:
Chronic myeloid leukemia (CML) is genetically characterized by the presence of the reciprocal translocation t(9;22)(q34;q11), resulting in a BCR/ABL gene fusion on the derivative chromosome 22 called the Philadelphia (Ph) chromosome. In 2-10% of the cases, this chimeric gene is generated by variant rearrangements, involving 9q34, 22q11, and one or several other genomic regions. All chromosomes have been described as participating in these variants, but there is a marked breakpoint clustering to chromosome bands 1p36, 3p21, 5q13, 6p21, 9q22, 11q13, 12p13, 17p13, 17q21, 17q25, 19q13, 21q22, 22q12, and 22q13. Despite their genetically complex nature, available data indicate that variant rearrangements do not confer any specific phenotypic or prognostic impact as compared to CML with a standard Ph chromosome. In most instances, the t(9;22), or a variant thereof, is the sole chromosomal anomaly during the chronic phase (CP) of the disease, whereas additional genetic changes are demonstrable in 60-80% of cases in blast crisis (BC). The secondary chromosomal aberrations are clearly nonrandom, with the most common chromosomal abnormalities being +8 (34% of cases with additional changes), +Ph (30%), i(17q) (20%), +19 (13%), -Y (8% of males), +21 (7%), +17 (5%), and monosomy 7 (5%). We suggest that all these aberrations, occurring in >5% of CML with secondary changes, should be denoted major route abnormalities. Chromosome segments often involved in structural rearrangements include 1q, 3q21, 3q26, 7p, 9p, 11q23, 12p13, 13q11-14, 17p11, 17q10, 21q22, and 22q10. No clear-cut differences as regards type and prevalence of additional aberrations seem to exist between CML with standard t(9;22) and CML with variants, except for slightly lower frequencies of the most common changes in the latter group. The temporal order of the secondary changes varies, but the preferred pathway appears to start with i(17q), followed by +8 and +Ph, and then +19. Molecular genetic abnormalities preceding, or occurring during, BC include overexpression of the BCR/ABL transcript, upregulation of the EVI1 gene, increased telomerase activity, and mutations of the tumor suppressor genes RB1, TP53, and CDKN2A. The cytogenetic evolution patterns vary significantly in relation to treatment given during CP. For example, +8 is more common after busulfan than hydroxyurea therapy, and the secondary changes seen after interferon-alpha treatment or bone marrow transplantation are often unusual, seemingly random, and occasionally transient. Apart from the strong phenotypic impact of addition of acute myeloid leukemia/myelodysplasia-associated translocations and inversions, such as inv(3)(q21q26), t(3;21)(q26;q22), and t(15;17)(q22;q12-21), in CML BC, only a few significant differences between myeloid and lymphoid BC are discerned, with i(17q) and TP53 mutations being more common in myeloid BC and monosomy 7, hypodiploidy, and CDKN2A deletions being more frequent in lymphoid BC. The prognostic significance of the secondary genetic changes is not uniform, although abnormalities involving chromosome 17, e.g., i(17q), have repeatedly been shown to be ominous. However, the clinical impact of additional cytogenetic and molecular genetic aberrations is most likely modified by the treatment modalities used.
Authors:
Bertil Johansson; Thoas Fioretos; Felix Mitelman
Related Documents :
7723278 - Karyotype findings and molecular analysis of the bcr gene rearrangement supplementing t...
3866248 - Chromosomal localization and characterization of c-abl in the t(6;9) of acute nonlympho...
6958358 - Variant philadelphia chromosome translocations in two patients with chronic myelogenous...
3332858 - Chromosome abnormalities in cml.
8671728 - The centromere as a target for the induction of chromosome damage in resting and prolif...
15581838 - Partial trisomy 18q11.2-->qter due to de novo unbalanced translocation of chromosomes 1...
Publication Detail:
Type:  Journal Article; Research Support, Non-U.S. Gov't; Review    
Journal Detail:
Title:  Acta haematologica     Volume:  107     ISSN:  0001-5792     ISO Abbreviation:  Acta Haematol.     Publication Date:  2002  
Date Detail:
Created Date:  2002-03-28     Completed Date:  2002-06-11     Revised Date:  2007-11-15    
Medline Journal Info:
Nlm Unique ID:  0141053     Medline TA:  Acta Haematol     Country:  Switzerland    
Other Details:
Languages:  eng     Pagination:  76-94     Citation Subset:  IM    
Copyright Information:
Copyright 2002 S. Karger AG, Basel
Affiliation:
Department of Clinical Genetics, Lund University Hospital, Sweden.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:
Cytogenetic Analysis*
Disease Progression
Evolution, Molecular*
Gene Rearrangement
Humans
Leukemia, Myelogenous, Chronic, BCR-ABL Positive / diagnosis,  genetics*,  therapy
Philadelphia Chromosome
Translocation, Genetic

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  Cytogenetic and molecular monitoring of residual disease in chronic myeloid leukaemia.
Next Document:  Sequential transformation of t(8;13)-related disease: a case report.